Navigation Links
Taiho Pharmaceutical Announces Results of Randomized Phase II Clinical Trial with Novel Antitumor Agent TAS-102
Date:7/22/2011

ctory to standard chemotherapy and for which there is presently no established therapy.

About TAS-102 Phase II clinical trial:

The Phase II trial was conducted with the participation of 172 patients at 20 medical institutions in Japan from August 2009 to April 2010. The target for the study is an area for which there is currently no fully established therapy -- specifically, patients refractory to standard chemotherapy for metastatic colorectal cancer who have received at least two or more regimens containing a fluoropyrimidine, irinotecan, and oxaliplatin. Patients were randomly assigned to the TAS-102 (114 cases) or a placebo (58 cases). The primary endpoint was overall survival. TAS-102 and placebo were administered at dose of 70mg/m2/day twice daily for five days followed by two days rest and repeated twice. This was followed by a 14-day rest period to make a 28-day schedule for one course. In both cohorts, the 28-day cycle was repeated until the established criteria for termination were met.

About Taiho Pharmaceutical:

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology. Its corporate philosophy takes the form of a pledge: "We strive to improve human health and contribute to the enrichment of society." In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan and around the world for developing evidence-based medicines for the treatment of cancer. In areas other than oncology, as well, the company creates quality products that effectively treat medical conditions and can help improve people's quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer over-the-counter medicinal products that support people's efforts to lead fulfilling and rewarding lives. For more information about Taiho Pharmaceutical, please visit '/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
(Date:1/23/2015)... TOWN, South Africa , Jan. 23, 2015   ... distributor of personal protective equipment for all forms of ... the flagship Leatt-Brace® neck brace, announced today that the ... racing federation, now requires all riders to wear a ...
(Date:1/23/2015)... plc (NYSE: MNK ) announced today that ... program. The open-ended authorization permits the company to repurchase ... "Funding additional initiatives and seeking attractive ... to pursue a range of focused growth strategies," said ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
(Date:1/22/2015)... (PRWEB) January 22, 2015 For over 20 years, ... Oceanside and Vista area has treated just about every ... personal injury circumstances. And for those same twenty-plus years, the ... of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the American ... effort to further promote visibility and adoption of the top ... AMA journals available via its subscription services, EBSCO will now ... , Long known as both a subscription agency and ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting ... auto insurance policy . , Some types of vehicles cannot ... the newly released blog post to see if their vehicle qualifies ... vehicles are some of the cars that cannot be covered by ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... further evidence to suggest that an enzyme secreted by the ... for new drugs to combat the deadly infectious disease. ... G (PknG), as a promising drug target back in 2004. ... is the secret weapon that enables the TB bug, Mycobacterium ...
... More bicycle riding and other lifestyle changes are urgently needed ... health and could also threaten the economy, the World Health ... indirectly to about 77,000 deaths per year in the region, ... is on the health of the people. If the trend ...
... have announced the birth of the first baby to be produced ... then frozen and defrosted for later use. ,The ... or who cannot be administered drugs that help egg maturation in ... around one year old, was born in Canada after work at ...
... advocates called Monday for tougher regulations on tobacco, as ... ways of boosting global efforts to stop smoking. ... Health Organisation (WHO) aims to find ways of harmonising ... advertising and protection from second-hand smoke. ,Hatai ...
... sleeping under insecticide-treated bed nets might protect older children ... transmission originates from adults and children over five years ... and are more attractive to mosquitoes. ,Current ... children and pregnant women in order to achieve over ...
... recognizing familiar smells could be experiencing an early sign of ... ,Scientists already know that the first lesions of the ... of the brain that is home to olfactory senses. ... tested 589 people aged between 54 to 90, and asked ...
Cached Medicine News:Health News:Structure of TB Enzyme Points the Way to New Drugs: Study 2Health News:UN Calls for Pedal Power to Reduce Environmental Damage 2Health News:First Baby Born from Eggs Matured and Frozen in the Lab 2Health News:Tougher Tobacco Rules Urged at Global Anti-smoking Talks 2
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
This agarose provides superior resolution of small PCR fragments and primers at lower concentrations than standard agaroses. A 3% gel clearly resolves a 10 bp ladder, and a 4% gel approaches the reso...
The PK TP System utilizes fixed chicken erythrocytes sensitized with components of the pathogenic T. pallidum (Nichols Strain) to perform a qualitative screening of Treponema pallidum in human serum ...
... donors on the PK7200 Automated Microplate System, ... attached to a gelatin particle for the ... of the CMV assay as compared to ... use of a gelatin particle as the ...
Medicine Products: